CNBC Reputable source
Samsung Biologics bids $1.8 billion in cash for Switzerland's PolyPeptide Group
Overall sentiment: Neutral
Open original · Jenny Lee
Published Jul 20, 2026 · Retrieved Jul 20, 2026
business science health technology
- Samsung Biologics offers 1.46 billion Swiss francs ($1.8 billion) to acquire PolyPeptide Group Newsworthy Reliable Neutral
- PolyPeptide shareholders will receive 44.31 Swiss francs per share under the public tender offer Newsworthy Reliable Neutral
- The acquisition is expected to close by the end of 2026, marking Switzerland's largest biopharmaceutical M&A Newsworthy Reliable Neutral
- Samsung Biologics aims to expand into peptide therapeutics, driven by rising demand for obesity treatments Newsworthy Reliable Positive
- PolyPeptide Group specializes in peptide-based active pharmaceutical ingredients and therapeutic peptides Relevant Reliable Neutral
- Peptide therapeutics include GLP-1 drugs that mimic hormones to reduce appetite and regulate blood sugar Relevant Reliable Positive
- Samsung Biologics will broaden its offerings from antibody drugs to peptide-based GLP-1 therapies Relevant Reliable Positive
- The deal expands Samsung Biologics' global footprint via PolyPeptide's R&D and manufacturing in five countries Relevant Reliable Positive
Type: standard news · Analysis confidence: 95%
Used in syntheses
- Samsung Electronics America cuts 739 jobs moving HQ to Texas • TSMC accelerates $265 billion U.S. AI-driven chip expansion • ASML nears $700 billion valuation on AI demand • Nvidia faces Google and Moonshot AI competition • Micron drops 30% despite record AI earnings • Samsung Biologics acquires PolyPeptide for $1.8 billion • SK hynix warns of memory market risks amid $739 billion capacity expansion • Nvidia expands D.C. office, readies RTX Spark for Windows on Arm
- Samsung Electronics America cuts 739 jobs relocating HQ to Texas • TSMC accelerates $265B Arizona expansion amid AI chip demand • Samsung Biologics bids $1.8B for PolyPeptide • Micron shares fall 30% despite record AI-driven revenue • ASML stock up 60% in 2026, nearing €1 trillion valuation • Intel lowers FY2026 EPS forecast while advancing AI manufacturing • UFC's Alexandre Pantoja aims for flyweight title rematch after injury • NVIDIA leases 27,600 sq ft office in Washington D.C.